There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

Public health officials in Alaska have reported three cases of Clade I mpox in people with no recent travel history, raising concerns about local transmission of the virus in the US.

The cases were confirmed in Anchorage in October 2026, shortly after California's Stanislaus County reported four cases of Clade I mpox, the strain responsible for the 2024 global outbreak.

While the cases point to possible community transmission, health officials said the risk to the general public remains low.

Three Clade I Mpox Cases Reported In Alaska

Three cases of mpox (monkeypox) were confirmed in Anchorage in October 2026, according to the Alaska Public Health Alert Network.

All three patients are male. An epidemiological link has been identified between the first two cases, while no link has been established for the third.

None of the patients reported out-of-state travel.

The first two cases were caused by Clade Ib mpox, marking the first reported Clade I infections in Alaska. Clade determination for the third case is pending.

One patient was briefly hospitalised. All three are currently isolating and recovering, while investigations continue.

The global mpox outbreak that began in 2022 was caused by Clade IIb. Since March 2026, imported Clade I cases have increased in the US, with presumed local transmission reported in 15 jurisdictions since August 2026.

Also read: 1,370 Mpox Cases, 7 Deaths Reported In July: WHO Says Risk Remains Moderate

California Reports Four Clade I Mpox Cases

Public health officials in California's Stanislaus County have reported four mpox cases. Two have been confirmed as Clade I, while testing is underway for the other two.

Three individuals had no recent international travel history, raising concerns about local transmission. The travel history of the fourth person is still being assessed.

The cases suggest possible community transmission. However, county officials have said the risk to the general public remains low.

US Reports Sustained Clade I Mpox Transmission

The Center for Outbreak Response Innovation (CORI), supported by the Johns Hopkins Bloomberg School of Public Health and the CDC's Center for Forecasting and Outbreak Analytics, has classified the US as being in Scenario 4: Sustained Transmission for Clade I mpox.

This indicates ongoing person-to-person transmission chains in some jurisdictions, primarily among adults with multiple sexual partners, including sex workers and men who have sex with men (MSM).

The CDC reported more than 90 Clade I cases across at least 23 states and Puerto Rico as of October 14, 2026. Domestic transmission had been reported in 10 jurisdictions, with additional cases involving people without recent international travel.

Read More: Mpox Spreads in Guinea-Bissau, Half Of Suspected Cases Are Children

Why Is Clade I Mpox A Concern?

Clade I has historically been associated with more severe illness and higher case-fatality rates than Clade II.

Its historical case-fatality rate has been estimated at 1% to 10%, compared with approximately 1% to 4% or lower for Clade II. However, recent Clade I outbreaks have recorded substantially lower mortality, particularly where appropriate medical care is available.

The 2024 global outbreak was driven largely by Clade I, particularly the Clade Ib sub-lineage. On August 14, 2024, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC).

What Is Mpox?

Mpox is a viral zoonotic disease caused by the monkeypox virus, which belongs to the Orthopoxvirus genus, the same family of viruses as smallpox.

It spreads through close contact with an infected person, including skin-to-skin and sexual contact, exposure to sores or bodily fluids, and contact with contaminated items such as bedding and towels. Transmission can also occur through contact with infected animals.

What Are The Symptoms Of Mpox?

Symptoms generally appear 5 to 21 days after exposure and include:

• Skin rash
• Fever
• Sore throat
• Headache
• Muscle and body aches
• Fatigue
• Swollen lymph nodes

Most people recover within two to four weeks. However, severe illness can occur, particularly in children, pregnant women and immunocompromised people.

GLP-1 drugs such as Ozempic and Wegovy can reduce cardiovascular events and deaths in people with type 2 diabetes (T2D) and some people with obesity. However, stopping treatment may affect these benefits.

Around 20–50% of patients discontinue GLP-1 therapy within the first year. Previous studies have linked discontinuation to weight regain and worsening blood sugar, blood pressure and cholesterol levels.

Now, a study published in The Lancet Regional Health has found that people with type 2 diabetes and no previous cardiovascular disease who stopped GLP-1 treatment had nearly twice the risk of heart attack, stroke or death from any cause compared with those who continued.

"In people with T2D and without previous cardiovascular disease, interrupting a therapy with GLP-1RA was associated with a higher risk of a composite of myocardial infarction, stroke, or death from any cause compared to those continuing the treatment," said researchers from IRCCS MultiMedica in Milan, Italy.

However, the observational study cannot establish that stopping GLP-1 drugs directly caused the increased risk. Researchers also did not know why patients discontinued treatment, which could have been due to side effects, cost or underlying illnesses such as frailty or cancer.

What Did The Study Find?

Also read: After Ozempic, Wegovy And Other GLP-1 Drugs, More US Men Opt for Cosmetic Treatments

Researchers analysed electronic medical records from more than 300 diabetes clinics in the Italian Association of Clinical Diabetologists (AMD) database, covering 2004–2024.

They identified more than 80,000 people with type 2 diabetes and no established cardiovascular disease who had started GLP-1 treatment.

Those who continued treatment took the medication for nearly three years on average, compared with just over one year among those who stopped.

The combined risk of non-fatal heart attack, non-fatal stroke or death from any cause was nearly twice as high among those who discontinued treatment.

• Those who stopped: About 4 events per 100 people per year.
• Those who continued: About 2 events per 100 people per year.

People With Obesity Had Higher Risks

Read More: Ozempic, Zepbound: US FDA Orders New Warning Over Rare Eye Risk

Among those who discontinued treatment, the risks of adverse outcomes were higher in people with obesity (body mass index of 30 or above) than in those without obesity.

Interestingly, changes in weight, blood sugar and blood pressure after stopping treatment were modest and similar among those who subsequently experienced a heart attack, stroke or death and those who did not.

This suggests that changes in these risk factors may not fully explain the higher rates of adverse outcomes.

Should You Stop Ozempic Or Wegovy?

Lead author Antonio Ceriello, head of diabetes research at IRCCS MultiMedica, said the association between stopping GLP-1 receptor agonists and poorer cardiovascular outcomes was "not a complete surprise". However, he noted that the scale of the association was significant, ABC News reported.

The researchers said long-term GLP-1 use may be important for maintaining health benefits in people with type 2 diabetes, but further studies are needed to establish whether stopping treatment directly increases cardiovascular risk or reflects worsening underlying health.

People taking Ozempic, Wegovy or other GLP-1 medications should discuss any decision to stop treatment with their doctor.

Eli Lilly's oral weight-loss drug Foundayo, that received FDA approval in April 2026, has shown promise in reducing the severity of obstructive sleep apnoea (OSA) in a recent trial.

OSA is a condition in which breathing repeatedly gets interrupted during sleep. In a late-stage clinical trial, the medicine reduced the repeated starting and stopping of breathing by up to 44% over 52 weeks in adults with moderate-to-severe sleep apnoea and overweight or obesity.

The findings from the phase 3 ATTAIN-OSA clinical programme were presented at the American Heart Association's Scientific Sessions 2026 on November 9 and published simultaneously in JAMA. The study included 712 participants, divided into two groups based on whether they were using positive airway pressure (PAP) therapy.

Eli Lilly plans to submit the findings to the US Food and Drug Administration (FDA) by the end of 2026 to seek approval for Foundayo as a treatment for moderate-to-severe obstructive sleep apnoea in adults with overweight or obesity.

Foundayo Reduces Sleep Apnoea Episodes

Also read: Lancet Study Says Obesity Drug Mazdutide Shows 18% Weight Loss In 32 Weeks: How Does It Compare To Wegovy?

The trial evaluated Foundayo, also known by its generic name orforglipron, in two separate studies. One involved 363 adults who were not using PAP therapy, while the other included 349 participants who continued using it.

After 52 weeks, the drug reduced the number of breathing interruptions per hour, measured using the apnoea-hypopnoea index (AHI).

The findings included:

• Participants not using PAP therapy: Breathing interruptions fell by 43.8% compared to a 6.3% reduction in the placebo group.
• Participants using PAP therapy: Breathing interruptions fell by 27.5% compared to a 3% reduction in the placebo group.
• Better oxygen levels: Sleep apnoea-related oxygen deprivation, measured through hypoxic burden, fell by 55.9% in the group not using PAP and 45.8% in the group using PAP.

The drug also helped some participants reach remission or mild disease. According to Lilly's reported efficacy analysis, this included 31.5% of participants not using PAP therapy and 19.6% of those using it.

Can Foundayo Replace CPAP Therapy?

Also read: Ozempic, Mounjaro Users Report Burning Skin Sensation: What Is Allodynia?

Continuous positive airway pressure (CPAP), a form of PAP therapy, remains a standard treatment for obstructive sleep apnoea. It uses a machine to deliver a steady flow of air through a mask, keeping the airway open during sleep.

The ATTAIN-OSA programme included participants who were not using PAP therapy as well as those who continued using it. The results suggest that Foundayo could benefit both groups, but they do not establish that patients can stop using CPAP.

Vaishnavi Kundel, the study's presenting author and Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, said, “If approved to treat obstructive sleep apnea, orforglipron could be a promising oral pharmacologic option for people with overweight or obesity and this condition. A convenient daily pill may help expand access to treatment for sleep apnea, and it could potentially be used with CPAP or other therapies to better meet individual patient’s needs.”

More About Foundayo

Also read: Ozempic, Zepbound: US FDA Orders New Warning Over Rare Eye Risk

Foundayo is an oral glucagon-like peptide-1 (GLP-1) receptor agonist. It is taken once daily and works by mimicking the GLP-1 hormone, which helps regulate appetite, calorie intake and blood glucose levels.

By reducing appetite and supporting weight loss, the drug may help address one of the important risk factors of obstructive sleep apnoea.

Excess weight, especially around the neck and upper airway, can increase the likelihood of airway narrowing or collapse during sleep. When the airway repeatedly becomes blocked, breathing interruptions occur and blood oxygen levels can fall.

Participants taking Foundayo lost an average of 11.5% of their body weight in the study group not using PAP therapy and 11.2% in the group using it.

Why Is Obstructive Sleep Apnoea A Concern?

Obstructive sleep apnoea is a breathing disorder related to sleep in which the muscles and soft tissues of the upper airway relax during sleep, causing the airway to narrow or become temporarily blocked.

This results in repeated pauses in breathing or episodes of shallow breathing, disrupting sleep and reducing oxygen levels. Common symptoms include:

• Loud and constant snoring
• Episodes of gasping or choking during sleep
• Waking up frequently during the night
• Morning headaches
• Excessive daytime sleepiness
• Difficulty concentrating and irritability